LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation

30/07/2020
POSITION PAPER

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation

The European Association for Bioindustries (EuropaBio) and the Biotechnology Innovation Organization (BIO) welcome the opportunity to provide comments on the European Strategy for Data. Our Organisations commend the European Commission for their efforts to establish a policy framework for data with a focus on accelerating research, innovation and economic growth, particularly in the life sciences. To realize the potential of promising biotech innovations, life sciences researchers around the world require a robust and reliable global ecosystem for data; an ecosystem that allows for timely access to a wide range of data sets and where restrictions, if any, on international data flows should be transparent, limited in scope and the least trade restrictive to achieve a legitimate public policy objective.

Our Organisations are hopeful that a collaborative dialogue will help shape a policy framework for the collection, use, and international transfer of data that will enrich scientific partnerships between Europe and the U.S. and enable the next generation of data-driven advances in bioscience and life sciences innovations to be developed for the benefit of mankind. As acknowledged in the European Strategy for Data, the convergence of big data and advances in biotechnology, across the spectrum of the life sciences, is unleashing a new wave of innovations, particularly from SMEs, with the potential to profoundly improve quality of life around the world. Medicine will be revolutionized by better diagnostics and cures for diseases. Food security will be improved by enhanced quality and quantity in food and feedstuffs. Our ability to respond to climate change will improve by moving the world towards biobased and zero-waste economies.

Recognizing and respecting the values of privacy, security, safety, and ethics, our Organisations encourage the creation of a research and innovation-friendly European data policy framework that enables biotech innovation and strengthens scientific collaborations with researchers around the world. As part of an innovation-friendly data policy framework, for example, our Organisations believe that addressing certain ambiguities in the implementation of the General Data Protection Regulation (GDPR) across European Union Member States would enable data use to support cross-border scientific collaborations that benefit the public health. In addition, our Organisations recognize the potential of the European Reference Networks in the rare disease space, for instance, and how a broader policy framework which reinforces data collection, interoperability, and cross-border data sharing will accelerate breakthrough biotechnology innovations to treat patients waiting for cures.

We are encouraged that through a collaborative conversation in the context of this EU Strategy on Data we can develop policy solutions that enable data-driven innovations in the life sciences and address current challenges. Our Organisations stand ready to serve as a resource and share our collective perspectives.

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

Health Biomanufacturing: Feedstock for Preparedness and Resilience


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.